ABVC ABVC BioPharma, Inc: Enterprise Value to EBITDA Ratio
ABVC BioPharma (ABVC) develops proprietary plant-based treatments for ADHD and depression, the prospects of which depend on regulatory approval in the US and Taiwan. The business relies on targeted therapy with minimal side effects and the implementation of diagnostic systems. The current EV/EBITDA ratio is 0.00. The market capitalization trend on the GURU.Markets platform clearly demonstrates the valuation dynamics of this biopharmaceutical asset.
Comprehensive metric breakdowns and analytics for abvcpharma.com (ABVC)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
Debt to Equity ABVC BioPharma|ABVC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital ABVC BioPharma, Inc.|ABVC - Company Aggregate Debts|Debts to Book Capitalization ABVC BioPharma, Inc|ABVC - Company Long-Term Debt|Company Current Liabilities ABVC BioPharma|Quick Ratio abvcpharma.com
- financial results and valuation multiples details:
ABVC - Net Income|Future Profit ABVC BioPharma|ABVC - Company Value to Net Income|Forward P/E Multiple ABVC BioPharma|ABVC - Price/Earnings to Growth Ratio|EV/EBITDA Multiple ABVC BioPharma, Inc|ABVC - Operating income before deduction of amortization|Earnings per share for the last twelve months ABVC BioPharma|ABVC - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months abvcpharma.com|ABVC - Earnings per share trend in current year|Earnings growth forecast for next year ABVC BioPharma
Fundamental company analysis:ABVC BioPharma Inc ABVC
Given the significant clinical trial expenditures of ABVC BioPharma (ABVC) and its patent monetization model, the Enterprise Value to EBITDA ratio allows for a business valuation that accounts for debt load and depreciation. This chart reflects the real price of assets relative to operating profit, where a decline in the metric signals that the company is undervalued, while a prolonged minimum may indicate capital stagnation.
Who ABVC BioPharma competes with
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|EV/EBITDA Multiple MannKind Corp MNKD|Amphastar - EV/EBITDA Multiple|PCRX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SPRY (ARS Pharmaceuticals) - Enterprise Value to EBITDA Ratio|TBPH (theravance.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AQST (Aquestive Therapeutics, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio scPharma (SCPH)|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SXTC (China SXT Pharmaceuticals, Inc.)|Eupraxia Pharmaceuticals, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Invizyne Technologies EXOZ|oramed.com (ORMP) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Entera Bio (ENTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MindWalk Holdings|cumberlandpharma.com - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple QNTM|FGEN (FibroGen Inc) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TELO (Telomir Pharma)|EV/EBITDA Multiple Rani Therapeutics Holdings RANI|SNYR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation RLYB (Rallybio Corporation)|lexariabioscience.com (LEXX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pulmatrix Inc|PTHL (Pheton Holdings Limited) - EV/EBITDA Multiple|EV/EBITDA Multiple Aptorum|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple impactbiomedinc.com (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals, Inc.)|cbdMD Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRFX: Enterprise Value to EBITDA Ratio|CYTO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LIPO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio optinose.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pieris Pharmaceuticals, Inc.|Procaps Group - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SLRN (Acelyrin, Inc.)|EV/EBITDA Multiple tffpharma.com TFFP
